(Q33370081)

English

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

H Hirte

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

I B Vergote

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J R Jeffrey

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

R N Grimshaw

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S Coppieters

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

D Tu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A Sadura

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M Brundage

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

L Seymour

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

0 references

publication date

25 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

102

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

300-308

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16442153%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

randomized experiment

0 references

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Matrix metalloproteinases and their inhibitors in tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Regulation of matrix metalloproteinase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Clinical importance of metalloproteinases and their inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Matrix metalloproteinases in colorectal cancer: is it worth talking about?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.020

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370081&oldid=1505070477"